CXCL9 may serve as a potential biomarker for primary Sjögren's syndrome with extra-glandular manifestations.

"table s1 ) and 20 healthy individuals. to avoid confounding effects collect all data"

"Declarations Ethics approval and consent to participateThe study was approved by the the ethics committee of Wenzhou Medical University’s First Affiliated Hospital approved the study (#16024). All subjects provided written informed consent to participate in the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The research was funded by grants from the Wenzhou Science and Technology Plan Project (Y20210852); the Education Department Project of Zhejiang Province (Y202045501); the First Affiliated Hospital of Wenzhou Medical University (FHY2019093)."